Leaps by Bayer co-led a $55m series A round for cancer immunotherapy developer Triumvira Immunologics and is getting two board seats.
US-based oncology therapy developer Triumvira Immunologics has closed a $55m series A round co-led by pharmaceutical and agricultural product manufacturer Bayer through its Leaps by Bayer unit.
The round was co-led by venture capital firm Northpond Ventures and also featured drug discovery services firm Viva Biotech, Oceanpine Capital and existing investors including investment bank Bloom Burton and Centre for Commercialization of Cancer Immunotherapy (C3i).
Founded in 2015, Triumvira is working on a technology platform that will engineer T-cells designed to…
